Lipella Pharmaceuticals Inc (LIPO)
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company listed on OTC Markets under the symbol LIPO. The company focuses on reformulating active ingredients from existing generic drugs and adapting those formulations for specific medical uses. Its development pipeline includes LP-10, a tacrolimus formulation being studied for radiation-induced hemorrhagic cystitis; LP-310, also based on tacrolimus and aimed at oral lichen planus; LP-410, an oral liposomal tacrolimus formulation for oral graft-versus-host disease; and LP-50, an intravesical immunoglobulin formulation being developed for non-muscle invasive bladder cancer. Lipella Pharmaceuticals was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, the company filed a voluntary Chapter 11 reorganization petition in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-LIPO
|
$0.00070
|
40.0% Upside
|
Undervalued
|
Not available
|
Not available
|
Weak
|
0.0%
|
December 2, 2026
|
2.31 K
|
-1.589 M
|
99.1%
|
93.7%
|
-33.1
|
89.6%
|
